China performs approximately 250,000 cardiac surgeries annually, including about 60,000 coronary artery bypass grafting (CABG) procedures. In minimally invasive cardiac surgery, valvular intervention, and artificial heart technology, China has reached internationally advanced levels. For international patients requiring bypass surgery, valve replacement, or congenital heart disease surgery, this article introduces four verifiable top cardiovascular surgery specialists.
Current State of Cardiovascular Surgery in China
CABG Surgery: Approximately 60,000 patients undergo CABG annually in China. Research by Professor Zhao Qiang’s team at Ruijin Hospital, published in The Lancet, confirmed that quantitative flow ratio (QFR)-guided CABG significantly improves patient outcomes—a finding that may change global clinical decision-making standards for bypass surgery.
Minimally Invasive Cardiac Surgery: China has seen rapid development in minimally invasive valve surgery (MIS), transcatheter aortic valve replacement (TAVR), and minimally invasive CABG. Centers like Fuwai Hospital and Zhongshan Hospital now perform over 500 TAVR procedures annually.
Heart Transplantation: China performs approximately 500 heart transplants annually, with 1-year survival rates exceeding 90%, reaching internationally advanced levels. Professor Wang Chunsheng’s team at Zhongshan Hospital has completed over 300 heart transplants.
Artificial Heart: China’s domestically developed left ventricular assist devices (LVADs) such as “Yongrenxin” have been approved for clinical use, offering new treatment options for patients with end-stage heart failure.
Cost Comparison: Cardiac surgery in China costs approximately 1/5 to 1/4 of US prices. CABG costs about $100,000-200,000 in the US, compared to $11,000-21,000 at a Chinese tertiary hospital.
Top Cardiovascular Surgery Specialists
1. Dr. Zhao Qiang (赵强), Chief Physician—International CABG Authority
Basic Information:
Hospital: Ruijin Hospital, Shanghai Jiao Tong University School of MedicineTitle: Chief Physician, Professor, Doctoral SupervisorVice President of Ruijin Hospital, Director of Heart Center, Director of Cardiac SurgeryAreas of Expertise:
Coronary artery surgery: Off-pump beating-heart CABGMinimally invasive coronary bypassSurgical treatment of severe coronary artery diseaseKey Achievements and Data:
Performed over 25,000 cardiac surgeries; nearly 2,000 cases annuallyMarch 2026: Published FAVOR study in The Lancet confirming QFR-guided CABG significantly improves outcomes—potentially changing global CABG clinical decision standards2024: Published DACAB study in BMJ confirming dual antiplatelet therapy post-CABG reduces vein graft failure by 30-40%Pioneered off-pump beating-heart CABG in ChinaHonored as “Shanghai Craftsman” and “Shanghai Leading Talent”Source: Ruijin Hospital official website, Shanghai Jiao Tong University News, Sohu Health, Xinmin NewsIdeal for:
Multi-vessel coronary disease requiring CABGPatients with severe coronary artery diseasePatients seeking minimally invasive bypass techniques#### 2. Dr. Hu Shengshou (胡盛寿), Academician—China’s Cardiovascular Surgery Leader
Basic Information:
Hospital: Fuwai Hospital, Chinese Academy of Medical SciencesTitle: Academician of CAE, Chief Physician, Professor, PresidentDirector of National Center for Cardiovascular DiseasesAreas of Expertise:
Coronary artery surgery: CABGValvular surgery: Heart valve replacement and repairCongenital heart surgery: Complex CHD correctionArtificial heart: LVAD implantationKey Achievements and Data:
Performed over 4,000 cardiovascular surgeriesEstablished China’s coronary surgery treatment system; multiple techniques included in American cardiothoracic surgery continuing education curriculumPioneered development and clinical application of domestic LVADsChief Scientist of National “973 Project”Source: Fuwai Hospital official website, National Center for Cardiovascular Diseases, CAMSIdeal for:
Complex coronary artery disease requiring CABGValvular heart disease requiring replacement or repairEnd-stage heart failure patients considering LVAD or heart transplant#### 3. Dr. Wang Chunsheng (王春生), Chief Physician—China’s Heart Transplant Authority
Basic Information:
Hospital: Zhongshan Hospital, Fudan UniversityTitle: Chief Physician, Professor, Doctoral SupervisorDirector of Cardiac Surgery, Vice Director of Shanghai Cardiovascular Disease InstituteAreas of Expertise:
Heart transplantation: End-stage heart failureAortic surgery: Complex aortic aneurysm/dissectionMinimally invasive cardiac surgery: Minimally invasive valve surgeryLVAD (artificial heart) implantationKey Achievements and Data:
Performs over 1,000 cardiac surgeries annuallyCompleted over 300 heart transplants with 1-year survival exceeding 90%Performed over 1,000 minimally invasive valve surgeriesPerformed over 2,000 aortic surgeries2024: Successfully performed East China’s first HeartMate 3 LVAD implantationPrincipal author of China’s heart transplant technical standards and accreditation systemSource: Zhongshan Hospital official website, National Center for Cardiovascular Diseases, HKU-SZH official websiteIdeal for:
End-stage heart failure patients needing heart transplantComplex aortic aneurysm or aortic dissectionPatients needing minimally invasive valve surgery#### 4. Dr. Zheng Zhe (郑哲), Chief Physician—Minimally Invasive Cardiac Surgery Specialist
Basic Information:
Hospital: Fuwai Hospital, Chinese Academy of Medical SciencesTitle: Chief Physician, Professor, Doctoral SupervisorVice President of Fuwai HospitalAreas of Expertise:
Minimally invasive CABGHeart valve repair and replacementSurgical treatment of atrial fibrillationKey Achievements and Data:
Extensive experience in minimally invasive cardiac surgery, especially small-incision CABGParticipated in multiple international multi-center cardiac surgery clinical studiesSource: Fuwai Hospital official websiteIdeal for:
Coronary artery disease patients suitable for minimally invasive bypassValvular heart disease patients needing repair rather than replacementAtrial fibrillation patients requiring surgical ablation### Cost Reference for Cardiac Surgery in China
| Procedure | China Cost (USD) | US Cost (USD) | Savings |
|---|---|---|---|
| CABG | $11,000-21,000 | $100,000-200,000 | ~85% |
| Heart Valve Replacement | $11,000-21,000 | $100,000-200,000 | ~85% |
| TAVR | $28,000-42,000 | $50,000-80,000 | ~45-50% |
| Heart Transplant | $42,000-83,000 | $500,000-1,500,000 | ~90% |
| Congenital Heart Surgery | $7,000-14,000 | $50,000-150,000 | ~90% |
Note: Prices are reference estimates for tertiary hospitals, including surgery, hospitalization, and materials. TAVR costs are heavily influenced by valve device pricing.
Recommendations for International Patients
Pre-operative Evaluation: Comprehensive cardiac function assessment is required before heart surgery, including coronary angiography and echocardiography. Submit external hospital examination data to the target hospital for evaluation in advancePost-operative Recovery: Typically requires 2-4 weeks of inpatient rehabilitation after cardiac surgery, followed by 1-2 weeks of post-operative follow-up in ChinaMedication Management: Long-term anticoagulant/antiplatelet therapy is typically required after cardiac surgery; China can provide medications consistent with European and American standardsEmergency Contact: Choose hospitals with 24-hour emergency cardiac surgery capability